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Background: Although many birth control options are provided for women nowadays, the rate of 
unintended pregnancies remains high internationally and nationally. Novel contraceptive methods, 
such as contraceptive vaginal films, are needed to meet the users’ biological, social and economic 
needs. An established solvent-cast platform can potentially be an option for vaginal administration 
of progestins for contraception (1). The goal of this work is to the feasibility and versatility of film 
platform for incorporating progestins. Methods: A panel of progestins, desogestrel (DES), 
etonogestrel (ENG), dienogest (DNG) and ulipristal acetate (UPA) were chosen based on their 
different physiochemical properties and availability. The progestins were incorporated into a fast-
dissolved film formulation and the films were evaluated for appearance; weight; thickness; 
puncture strength; water content; disintegration time and drug content. Stability for each of these 
parameters was monitored for 3 months under two storage conditions (25°C/65%RH; 
40°C/75%RH). Additionally, in vitro dissolution was investigated using a USP 1 method.  Results: 
All four progestins could be successfully incorporated into the film formulation, despite their 
different lipophilicities. When comparing across progestin films for two dosing levels, differences 
were observed with respect to the physical characteristics of the progestin film. A decrease in drug 
content was observed for desogestrel (DES) films over 3 months. However, other progestin films 
remained stable throughout 3 months. Film physical properties were consistent throughout this 
time frame. The in vitro dissolution study showed that all four progestins released 80% of the drug 
within 15 minutes. Conclusion: Results demonstrated that the progestins could be formulated as 
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polymeric vaginal films, despite their different physiochemical properties. For ENG, DNG and 
UPA films, the physical characterizations of the progestin films remained stable for at least 3 
months. However, the amount of progestin located into the film impacted the puncture strength 
and water content of the films. This project demonstrated the capacity of the film to be applied for 
vaginal delivery of progestins. 
Keywords: progestin; polymeric vaginal films; formulation modification; physical 
characterizations 
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1.0  INTRODUCTION 
 
1.1 CONTRACEPTION 
1.1.1 The importance of birth control 
Reducing unintended pregnancy is one of the most important reproductive health goals identified 
by the United States Departments of Health and Human Services (2). Women who have an 
unintended pregnancy are at high risk of having adverse social, economic, and health outcomes 
for both the mother and the child (3, 4). The most common behaviors associated with unintended 
pregnancy include delayed or no prenatal care, smoking during pregnancy, and no breastfeeding. 
These behaviors subsequently cause low birth weight, preterm birth, miscarriage, infant death, or 
illness during childhood (5). 
Besides the adverse outcomes for the mother and the child, unintended pregnancy also 
consumes a significant amount of federal dollars. One study (6) estimated the annual cost to 
taxpayers of unintended pregnancy and birth in the United States. This study indicated that for 
every dollar spent on voluntary family planning services to prevent unintended pregnancy, about 
$4 are saved in short-term costs to the government for the medical care for the pregnancy and for 
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1 year of infant care after birth. Another report (7) indicated that every public dollar invested to 
avoid unintended pregnancies saves $5.68 in Medicaid expenditures that otherwise would have 
gone to pregnancy-related care; in 2010, that amounted to a net government savings of $10.5 
billion. Overall, birth control can not only improve the health outcomes of the newborns but also 
decrease its financial burden to society. 
However, family planning has remained as one of the most critical public health topics 
over the last century. According to a recent paper (2), which analyzed the incidence of unintended 
pregnancy through 2006, nearly half (49%) of the pregnancies in 2006 were unintended, slightly 
up from 48% in 2001. Another study (5) analyzed the unintended births in the U.S. from 1982 to 
2010. The authors reported that about 37% of births (only accounted for the number of live births) 
were unintended at the time of conception. The overall proportion of unintended births has not 
declined significantly since 1982. Moreover, the number is likely underestimated (8). Since 2001, 
the U.S. has not made progress on the issue of controlling unintended pregnancies, with the overall 
rate remaining high. Thus, it is essential to find optimal contraceptive options for women to 
minimize the unintended pregnancy rate.   
1.1.2 Mechanisms of contraceptive agents: menstrual cycles, ovulation and hormones 
Among all the FDA-approved, reversible birth control options, all methods with low failure rate 
(<10 pregnancies expected per 100 women) contain hormones. Necessary background information 
on hormones will be provided in this section.  
The menstrual cycle has four distinct phases: menstruation, the follicular phase, ovulation, 
and the luteal phase. Even though menstruation is generally considered as the first phase of the 
cycle, the follicular phase is the beginning of egg formation for fertilization. During this phase, the 
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pituitary gland releases follicle-stimulating hormone (FSH), causing 10 to 20 follicles to develop 
in the ovary. Usually, only one dominant follicle will develop into a mature egg when an 
appropriately high FSH level threshold is reached, while others die of atresia. The mature egg 
moves to the surface of the ovary, while other follicles will break down and be reabsorbed by the 
ovary. During this phase, the ovary produces oestrogen (estrogen), which causes the endometrium 
to thicken. Because of the increase in estrogen, the hypothalamus releases gonadotropin-release 
hormone (GnRH). The high-pulse release of GnRH, in turn, causes the pituitary gland to produce 
increased levels of luteinizing hormone (LH). This abrupt increase of LH triggers ovulation, which 
marks the end of the follicular phase. During ovulation, the mature egg enters the fallopian tube 
and moves towards the uterus. The lifespan of a mature egg is between 6 to 24 hours. If the egg is 
not fertilized, it will break down within 24 hours.  
During the luteal phase, the remnant of the follicle which released the egg will release large 
amounts of progesterone and some oestrogen. These hormones further cause thickening of the 
uterus. If fertilization does not occur, progesterone level decreases and the corpus luteum breaks 
down. The shredded uterine lining flushes out of the vagina as a mixture of blood, endometrial 
cells, cervical mucus, and vaginal secretions. This phase is called menstruation.  
Fertilization requires mature eggs and sperms. Even though the mature egg disintegrates 
shortly after ovulation, the sperm can remain active for a much longer time. Sperm can remain 
motile in cervical mucus for seven or more days after insemination  (9, 10). Further, sperm retains 
the ability to fertilize human ova in vitro after five days at room temperature (11). Thus, a critical 
step for contraception is to control ovulation.  
The rapid drop in estrogen-to-progesterone ratio suggests the luteinization of the ovarian 
follicle. Moreover, the LH peak correlates with the day of ovulation (12). This evidence 
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demonstrates how hormones control the menstrual cycle, including ovulation. On one hand, the 
increased amounts of estrogen will inhibit pituitary production and secretion of FSH and LH, 
particularly during the mid-cycle surge of those hormones. The decreased levels of FSH and LH 
further lead to the inhibition of the follicular development, ovulation, and corpus luteum formation 
(13). On the other hand, increased level of progesterone results in inhibition of ovulation, and 
changes in cervical mucus and the endometrium (14). Finally, increased amounts of estrogen and 
progesterone can inhibit the fertilization. These biological effects demonstrate the contraceptive 
uses of estrogen and progesterone. 
1.1.3 Estrogen and Progestin: Benefits and Risks 
Estrogens impact various reproductive tissues, including the uterus and breast. For example, they 
cause vaginal cornification and uterine growth. They are also highly involved in hormone-
responsive cancers, resulting in cell replication in breast or endometrial tumors (15). The initial 
action of estrogen is considered to be the same in each targeted tissue. Estrogen first binds to the 
nuclear estrogen receptor (ER). Following which an estrogen ligand causes conformational 
changes, resulting in interaction with either DNA sequence directly, or the promoter region of 
estrogen-responsive genes. Although there are two ERs, ERα and ERβ. They both belong to the 
steroid/thyroid hormone superfamily of receptors and share a common structural architecture. 
Therefore, the majority of estrogens bind to ERα and ERβ with similar affinities or potencies.  
Estrogens are proposed to be classified into two categories based on the structure of their 
responsive receptor complexes: the diethylstilbestrol type (Class 1) and the triphenylethylene type 
(Class 2) (15). The Class 1 estrogens are planar. They bind to an activated activating function 2 
(AF2) and produce an ER complex to initiate estrogen action. The Class 2 estrogens are angular. 
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These estrogens bind to an activated AF2b site. However, despite the structural differences, they 
act as contraceptive agents through the same endogenous effect, which is the inhibition of 
ovulation by preventing the production of FSH and LH (14).  
Progesterone is a natural hormone found in the human body, but not commonly used for 
therapy. The most commonly used synthetic hormones, which have properties similar to the 
progesterone, are progestins. The reason for their use is that compared to progesterone, the 
synthetic progestins have a more extended half-life and stable plasma levels for long-term use (16). 
One widely used purpose of progestin in the clinic is contraception. Similar to progesterone, 
progestin can inhibit the ovulation. Moreover, increased progestin levels can affect the cervix by 
decreasing the quantity and changing the quality of cervical mucus leading to interference with the 
sperm (17). Besides progesterone, there are different classes of progestins, such as 
retroprogesterone, progesterone derivatives, 17-hydroxyprogestrone derivatives, 19-
norprogestrone derivatives, 19-norestosterone derivatives, spirolactone derivatives. A review of 
these classes is shown in Table 1.1.3.1. Examples were obtained from the literature (18).   
Table 1.1.3.1. Classification of Progestins.  
Examples are taken from reference (18). 
Progestin Class Example 
Progesterone Natural progesterone 
Retroprogesterone Dydrogesterone 
Progesterone derivative Medrogestone 
17 α-Hydroxyprogesterone derivatives 
(pregnanes) 
Medroxyprogesterone acetate, megestrol 
acetate 
17α-Hydroxyprogesterone derivatives 
(norpregnanes) 
Gestonorone caproate, nomegestrol acetate 
19-Norprogesterone derivatives (norpregnanes) Demegestone, promegestone, nesterone 
19-Nortestosterone derivatives (estranges) Norethisterone, norethisterone acetate 
19-Nortestosterone derivatives (gonanes) Norgestrel, levonorgestrel, desogestrel, 
etonogestrel, dienogest 
Spirolactone derivative Drospirenone 
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The pharmacodynamics properties of progestins depend on not only their chemical 
structures but also the route of administration. For example, several studies (19, 20) demonstrated 
that after oral administration, synthetic progestins are rapidly absorbed, and maximum serum 
concentration is reached within 2-5 hours, which is faster than that observed with parenteral, 
vaginal, intramuscular, or transdermal administration. Many the synthetic progestins are 
metabolized in the liver and excreted via the urine. As for the biological activities of progestins, 
they are dependent on the binding affinities and binding efficiencies to the progesterone-receptors. 
There are different forms of progesterone receptors (PR), PR-A and PR-B. The two receptors are 
encoded by a single gene in human (18). Because of the control of distinct promoters, the 
difference in the two receptor types lies in the amino-acid sequence differences between the A-
form and the B-form, with molecular masses of approximately 81kDa and 115kDa respectively 
(21). PR-B can mediate the intermediate agonistic effects in several organs, while PR-A can act as 
a dominant repressor of PR-B with extensive responses to diminish other hormone (22). The 
progestin-receptor (P-PR) effects are tissue specific. PR presence has been demonstrated in 
multiple areas of the central nervous system as well as the gastrointestinal system (23, 24). 
Literature also indicates that progestins have the neuroprotective role in models of traumatic brain 
injury (25, 26).   
Either estrogen and progestin alone can prevent ovulation. The combined use of both 
estrogen and progestin is commonly implemented in a number of birth control products given that 
this combination can promote antigonadotropic and ovulation-inhibitory effects (14). For example, 
combined oral contraceptives can suppress the secretion of FSH and LH, lowering the systemically 
circulating concentrations of both FSH and LH levels within the first day of administration (27). 
However, continuous use of the combined oral contraceptives is required for inhibition of 
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ovulation. More importantly, in some cases, where a portion of women who cannot use estrogen, 
the single use of progestin is recommended. The majority women requiring progestin-only 
contraception have the potentials to develop deep vein thrombosis or estrogen-related cancers. 
Another reason may be breastfeeding since estrogen-containing products should not be used during 
this time. As a result, the progestin-only products have also been developed. 
 
The progestins, as the major active pharmaceutical ingredients (API) for most 
contraceptive methods, have been formulated in various drug delivery systems (DDS). According 
to a report by the United Nations (UN), Trends in Contraceptive Use Worldwide 2015, female 
fertilization (19%) and intra-uterus devices (IUD) (14%) are two common methods used by 
married or in-union women worldwide. Long-acting or permanent contraceptive methods are 
especially popular in Asia and North America, including sterilization, IUD, and implants. No 
single birth control option can meet the need for everyone, therefore short-term contraceptive 
methods have also been developed and are acceptable to some women. Reversible contraceptive 
methods, including transdermal patches and vaginal rings, are also worth mentioning, as they 
produce another acceptable product option to women.  
1.2 DOSAGE FORMS FOR HORMONAL CONTRACEPTION 
1.2.1 Transdermal patch (Ortho Evra® and Xulane®)  
The transdermal contraceptive patch is a thin plastic film that is adhered to the skin of a user. Just 
like oral contraceptive pills, the patch contains hormones, usually a combination of estrogen and 
progestin. Therefore, the contraceptive effects come from both estrogen and progestin. The 
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contraceptive patch needs to be changed weekly. After use for three (3) weeks continuously, the 
woman should leave the patch off for one week before starting a new dose. The failure rate of 
patches is 9% for typical uses and 0.3% for perfect use (28). The birth control patch is not only 
effective and convenient for contraception, but it also has other health benefits, such as relieving 
the menstrual cramps and alleviating bleeding.  
Transdermal drug delivery systems can avoid the difficulties in absorption and first pass 
metabolism in the gastrointestinal tract (29). The patch also has been shown to result in good 
patient compliance. In two clinical trials involving healthy adult women of child-bearing potential 
in the United States and Canada (30, 31), compliance was higher with the patch than with oral 
contraceptives. However, additional studies are needed to determine whether the patch can offer 
significant efficacy or safety advantages over other contraceptive methods. On the other hand, the 
patch is not as effective in overweight women (weighing more than 90 kg) as in women with lower 
body weight (32). The patch also has some common adverse reactions caused by hormones, such 
as breast symptoms, headache, application-site reactions, and dysmenorrhea (33). But it should be 
noted that these side effects would accompany any estrogen containing product. 
Ortho Evra® is the first transdermal patch approved for prevention of pregnancy(33) with 
a contact surface area of 20 cm2. It contains 6mg of norelgestromin (NGMN) and 0.6 mg of ethinyl 
estradiol (EE) and releases 150 µg/d and 20 µg/d, respectively (29). Ortho Evra® is no longer 
available in the U.S. but still available in Europe and Canada. Currently, the only available 
contraceptive patch in the U.S. is Xulane®, a generic Ortho Evra® Patch marked by Mylan 
Pharmaceuticals. Xulane® is a 14 cm2 patch containing the same hormones as Ortho Evra® with 
different dosage (4.86 mg NGMN and 0.53 mg EE). It will release approximately 150 mcg/d 
NGMN and 35 mcg/d EE. Pooled data from the clinical studies demonstrated that the steady state 
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of serum drug concentration is reached within two weeks of application. Serum concentrations of 
both APIs dropped slightly after patch replacement but recovered within 12 hours. Following 
removal of the patch, the contraceptive effects can be discontinued quickly (half-life for NGMN 
and EE are 28 hours and 17 hours, respectively). Since the patch will be attached to the skin, 
specific environmental changes may impact drug release. For example, increased EE exposures 
were observed associated with higher body temperature. Moreover, due to the estrogen component, 
Xulane®’s effects include increased cardiovascular risks or blood clotting among certain users. 
There are other combined estrogen and progestins patches on the market, but not for 
contraception. CombiPatch® is a prescription medicine used to treat severe hot flashes associated 
with menopause containing estradiol and norethindrone acetate. Another similar hormone patch is 
Climara Pro®, which contains estradiol and levonorgestrel. It is also used to treat menopause 
symptoms like hot flashes and to prevent osteoporosis (bone loss).   
1.2.2 Birth control implant (Nexplanon®/ Norplant) 
Birth-control implants are long-acting reversible contraceptive (LARC) forms with normally four 
years of contraceptive effect. The implants are usually small rods (for example, Nexplanon®: 4 
cm in length with a diameter of 2 mm) which are inserted under the skin of a women’s upper arm. 
The implant is unnoticeable, providing women a discreet contraceptive option. At the product’s 
expiration date, the old implant must be removed, and a new one is re-inserted if the woman wishes 
to continue contraception. Women are no longer under the protection of implants as soon as they 
are removed, and pregnancy may occur shortly after removal if no other form of contraceptive 
protection is used.  
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The mechanisms of contraceptive implants are similar because they all contain progestin 
solely as the active pharmaceutical ingredient (API). Ovulation suppression is the primary 
contraceptive mechanism. This can be full or partial suppression because of different progestins 
used. The evidence of ovulation is found in about 10% of cycles of a woman using implants in the 
first year (14). Another contraceptive mechanism of progestin is thickening of the cervical mucus. 
This inhibits sperm penetration, leading to prevention of fertilization (34).   
Nexplanon® is the only implant that is available in the U.S. It can prevent pregnancy for 
three years with the efficacy higher than 99%. It contains 68 mg of the synthetic progestin 
etonogestrel (ENG). Once inserted, it will release ENG from 60-70 mcg/day (in week 5-6) to 25-
30 mcg/day (at the end of the third year). Norplant was the first contraceptive insert approved by 
FDA, but is not currently available in the U.S. Norplant contains levonorgestrel (LNG) with the 
similar progestin level to that of the progestin-only oral contraceptives (75 mg of LNG). The 
contraceptive effects of Norplant are maintained for five years. In the first year, ovulation happens 
about 10% of cycles of a woman using Norplant. The LNG blood levels decline, and the ovulation 
occurs in 30% to 75% of cycles by the fifth year (35). Implants are the most effective forms of 
contraception with a one-year failure rate of around 0.05% (36). The reason is that, in the late stage, 
the implant remains effective through the progestin effects other than ovulation inhibition, 
probably through the inadequate development of a secretory endometrium (37). The major 
downside of the implant is that both insertion and removal need to be performed by professional 
healthcare providers.  
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1.2.3 Vaginal Ring (NuvaRing®) 
Intravaginal rings (IVR) are small flexible polymeric ring-shaped platforms which provide 
controlled release of drugs. IVRs provide protective therapeutic effects for one month or longer. 
There are serval IVRs currently marketed, including: Estring® (containing estradiol), Femring® 
(containing estradiol-acetate), Progering® (containing progesterone) and NuvaRing® (containing 
progestin and estradiol). However, Estring® and Femring® are mainly used for the treatment of 
vaginal atrophy. Progering® is only available in Chile and Peru. That makes NuvaRing® is the 
only contraceptive intravaginal ring available in the U.S.  
NuvaRing® is a non-biodegradable, flexible, transparent vaginal ring with an outer 
diameter of 54 mm and a cross-sectional diameter of 4 mm. It contains 11.7 mg etonogestrel (ENG) 
and 2.7 mg ethinyl estradiol (EE). After insertion, the ring will release 0.120 mg/d of ENG and 
0.015 mg/d of EE on average. Like other combined hormonal contraceptive methods, NuvaRIng® 
stops ovulation, as well as thickens the cervical mucus.  
For regular use, the ring stays inside vagina continuously for three weeks. After a three-
week period of use, it is removed for a 1-week break. During the break, the user will experience a 
menstrual period. The user should insert and remove the ring on the same day of the week and the 
same time. The failure of removing the ring for more than four weeks may result in no protection 
from pregnancy.  
Obviously, controlled release of hormones is one of the ring’s strengths. It provides a 
steady serum concentration of both estrogen and progestin. Also, the ring can be left in the vagina 
during intercourse. Most couples report no interference or discomfort, with neither partner feeling 
the presence of the ring in many cases. The ring can be removed before/ during intercourse if that 
is preferred. However, the discontinued time should be within 3 hours to maintain the efficacy of 
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birth control. The handling of NuvaRing® is its downside. It requires proper disposal. Even though 
the exact location within the vagina is not critical for clinical efficacy, the presence of the ring 
should be maintained for contraception. Thus, the user should check ring placement before and 
after intercourse. To maximize the ring’s contraceptive effects, on-time insertion, and removal are 
both crucial. Because of the 3-week-on, 1-week-off pattern, users might need reminders to stay on 
schedule, which is not suitable for those who have a hectic schedule and cannot stay on top of 
using NuvaRing® correctly. 
Similar to other combined hormone contraceptive options, NuvaRing® has some mild to 
serious side effects. Specific groups (women who smoke cigarettes and are over 35 years old) 
should consider the potential cardiovascular side effects due to estrogen in the ring. Other common 
adverse side effects include irregular bleeding, nausea or headaches, which usually subside after 2 
or 3 months.   
1.2.4 Intrauterine device (IUD) 
An intrauterine device (IUD) is a small T-shape plastic/ metal device inserted into the uterus to 
provide birth control effects. As one of the long-acting reversible contraceptive (LARC) methods, 
IUDs result in great satisfaction among users (38). There are two types of IUDs available on the 
market: Non-hormonal copper IUDs; and IUDs with progestins.  
ParaGard® is the only non-hormonal copper IUD available in the U.S. With correct use. It 
can protect users from pregnancy for up to 12 years with a one-year failure rate around 0.7% (39). 
The failure rates will increase over 12 years because of the decrease in copper, but the cumulative 
12-year failure rate is still low (2.2%) (40). It can also be used for emergency contraception up to 
5 days post sexual intercourse with the failure rate of 0.09% (41). Copper IUDs work primarily by 
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disrupting the mobility and morphology of sperms. Increasing the level of copper ions within the 
uterus acts as a spermicide (42). Several studies(43, 44) showed that the sterile foreign body 
reaction in the uterine cavity causes biochemistry and cellular changes which can influence the 
number of sperm reaching the uterine cavity and fallopian tubes. The changes can also damage the 
sperm itself, causing head-tail separation, which makes the sperm unable to fertilize (14).  
There are four brands of hormonal IUDs: Mirena®, Liletta®, Kyleena®, and Skyla®. The 
dosage and approval length for each hormonal IUD are summarized in Table 1.2.4.1. As shown in 
the table, all four IUDs contain the same progestin, levonorgestrel, but may differ in progestin 
loading level and release profile.  
Mirena® is a levonorgestrel (LNG)-releasing IUD with a failure rate less than 1%. It can 
prevent pregnancy for up to 5 years or even longer (45). The IUD requires insertion by a healthcare 
provider. After five years, Mirena® must be removed and replaced with a new IUD if continued 
contraceptive protection is desired. The most common adverse reactions are alterations of 
menstrual bleeding patterns, abdominal/ pelvic pain, amenorrhea, and headache/ migraine. The 
most important safety concern is that it may cause pelvic inflammatory disease (PID). Even though 
only 1% of the users get this serious pelvic infection, women should not use Mirena® if they have 
a history of pelvic infection or are at increased risk of infection. Since PID is often associated with 
a sexually transmitted infection (STI), which IUDs cannot prevent from, full health background 
screening should be performed before IUD insertion. The health care providers should also rule 
out other risk factors, like leukemia or acquired immune deficiency syndrome (AIDS). 
Liletta® is a pharmacologic equivalent to Mirena® with the same total amount of hormone. 
It releases slightly less hormone per day and has other differences, so it is not a generic to Mirena®. 
Liletta® serves as a cheaper substitute compared to Mirena®. Kyleena® is a newly approved IUD 
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manufactured by Bayer®. It is approved for the same length as Mirena® but releases fewer 
hormones. This device is a better option for women who would want to keep regular menstrual 
periods. Skyla® also releases fewer hormones than Mirena®, meaning more women will keep 
getting their periods, which is the same purpose as Kyleena®. Skyla® is smaller than other IUDs, 
making it more suitable for women who have not had their cervix dilated. However, Skyla® is 
only approved for three years, which is the shortest therapeutic period among all the IUDs. 
Table 1.2.4.1 Summarized table of all hormonal IUDs on the U.S. market.  
* Additional studies show that the devices are effective even longer than originally approved for: 7 years for 
Mirena®(45), and five years for Liletta®(46). 
Name Hormone Manufacturer Dose Approved Length 
Mirena® Levonorgestrel Bayer® 20 mcg/d 
(52 mg total) 
5 years 
(7 years*) 
Liletta® Levonorgestrel Allergan® and 
Medicines360® 
18.6 mcg/d  
(52 mg total) 
3 years 
(5 years*) 
Kyleena® Levonorgestrel Bayer® 17.5 mcg/d 
(19.5 mg total) 
5 years 
Skyla® Levonorgestrel Bayer® 14 mcg/d 
(13.5 mg total) 
3 years 
 
For all IUDs, both insertion and removal require professional health care provider 
participation. Women may experience cramping or pain during the IUD insertion/ removal process 
and immediately after (47). Other common side effects include irregular bleeding and spotting and 
increased chance of infection. All IUDs have risks of expulsion (the IUD is expelled from the 
uterus) and perforation (the IUD moves through the wall of the uterus). Copper IUD (ParaGard®) 
use may result in increased blood flow during menstrual periods and worse menstrual cramps. If 
women are opposed to the heavy menstrual bleeding, they can switch to a hormonal IUD. In fact, 
Mirena® is also FDA-approved for the treatment of heavy menstrual bleeding or menorrhagia. 
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There used to be controversial theories on whether IUDs are abortifacient or not. Some 
experts in human reproduction believed that IUDs with copper could disrupt implantation (48). 
There has been no definitive evidence showing that the IUD users have higher embryonic loss 
rates (42). Nowadays, the majority of people believe that the IUD works on the early stage of 
human reproduction as noted by the WHO scientific group, “They (IUDs)…interfere with steps in 
the reproductive process that take place before the ova reaches the uterine cavity”(43). The non-
abortifacient mechanism was also confirmed by American College of Obstetricians and 
Gynecologists (ACOG) in 1987 (14). The conclusion is useful for the users of specific religions 
as it may eliminate the fear of using IUDs.   
 
Since the development of combined estrogen and progestin oral contraceptive over 50 
years ago, almost all innovations of contraceptive methods have revolved around progestins. Novel 
progestins have been designed to decrease side effects, increase potency and half-life, and to 
manipulate agonist/ antagonist profiles to achieve optimal contraceptive effects (17). Also, modern 
delivery systems have achieved significant advances, specifically for progestins. Non-oral delivery 
systems (patch, ring, implant and IUD) will continue to be developed for progestins. These 
delivery systems can provide steady, continuous, safe administration and achieve higher user 
compliance. Polymeric vaginal films, a novel topical drug delivery system, may provide as a new 
birth control option for women. 
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1.3 POLYMERIC VAGINAL FILMS 
1.3.1 N-9 vaginal films (Non-hormone contraception films) 
The use of the polymeric film as a drug delivery system has attracted considerable attention in 
recent years. Many orally-dissolving products have been developed, such as Listerine 
PocketPaks®, TheraFlu® ThinStrips®, and Sudafed PE Quick Dissolve Strip®. Other than oral 
delivery, vaginal delivery routes have also been studied for polymeric films. The Vaginal 
Contraceptive Film® (VCF®) is the only FDA-approved vaginal film used for contraception. 
VCF® is a two-inch square soft soluble film that is manually inserted into the vagina at least 15 
minutes before intercourse. VCF® contains Nonoxynol-9 (N-9), an FDA-approved organic 
compound that can be used as a spermicide. N-9 can immobilize sperm and is widely used in three 
vaginal contraceptive forms: suppositories, gels, and films.  
VCF® is small and can be discreetly used. It is quickly dissolved by body fluids in the 
vagina, so it will not be noticed by most women and their partners during sex. VCF® washes away 
with the natural body fluids, so the users do not need to worry about removal or disposal. Use of 
this product does not require a prescription, and it is even available online. The easy-to-get, use-
on-site, and unnoticeable nature of VCF® makes it acceptable among some women. However, as 
a spermicide, VCF® has a relatively higher failure rate, compared to other birth control methods. 
A clinical study indicated that five vaginal contraceptives containing N-9 as spermicide have 
typical-use failure rates ranging from 10% to 20% (49). The N-9 VCF® has also been associated 
with increased risk of STIs. One WHO report indicated that N-9 does not prevent HIV infection 
and may even favor infection if used frequently. The sole use of VCF® will not prevent pregnancy 
efficiently. Therefore, other birth control options are strongly recommended. 
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1.3.2 The polymeric vaginal film: advantages and disadvantages 
The polymeric film delivery system is a thin and flexible strip of polymer which incorporate the 
API within. The API may be either dissolved or suspended in the polymeric film. It is a solid 
pharmaceutical product, and therefore APIs which are susceptible to hydrolysis can be stabilized 
using this dosage form. Low water content provides films with no need to incorporate preservatives 
for longer shelf-life. Additionally, polymeric films can be administrated with precise dose, easily 
transported and conveniently stored (5). As mentioned above, the use of oral-releasing polymeric 
films has been well-established. As a drug delivery site, the vagina presents several advantages, 
such as large surface area, abundant blood supply, no first-pass metabolism, and relatively high 
permeability to several drugs (50). This biological advantage allows some APIs to be quickly 
absorbed through the vagina into the blood. The APIs are then distributed systemically. Thus, the 
polymeric vaginal film is an ideal dosage form for both topical and systemic drug delivery. 
Moreover, compared to other vaginal DDSs, like vaginal gels and foams, the polymeric vaginal 
film causes less messiness and leakage (51, 52). Unlike vaginal gels or vaginal creams, vaginal 
films do not require applicators for product insertion. The films can be individually wrapped in 
flat, sealed packages. The flexibility makes films more resistible to physical forces, compared to 
tablets. Their portability provides advantage over gels, creams, and foams. Additionally, several 
published studies and products prove that the polymeric vaginal film has good acceptability (5). 
On the other hand, culture and religion differences, personal hygiene issues, and insertion 
difficulties should all be considered when using the polymeric vaginal film (53).  
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1.3.3 The progestin vaginal films 
The polymeric vaginal film, as a drug delivery system, has many advantages as mentioned above. 
It has potential for local and systemic drug delivery through the vagina. The literature reported that 
polymeric films could successfully incorporate arrange of compounds, including peptides and 
virus-like particles (VLP) for prevention of HIV (5, 52, 54-56). In the hope of achieving dual 
prevention products, our laboratory previously combined levonorgestrel (LNG) and dapivirine 
(DPV) into one film (57). The combined effects of contraception and HIV-prevention can be 
further developed as multi-purpose prevention therapy (MPT). To better understand the feasibility 
and versatility of this film platform, progestins other than LNG need to be tested. Since there are 
various classes of progestins on the market, the choice of progestins used for this work is critical. 
Lipophilicity was the main physicochemical characteristic considered. Given the solvent-casting 
manufacturing method used for films typically utilizes an aqueous-based polymer solution, the 
lipophilicity of progestins may affect the dispersion. A panel of progestins with different 
lipophilicities was selected in this work. (Table 1.3.3.1) As mentioned above, ENG is used in 
Nexplanon®, a long-acting contraceptive implant. Nexplanon® contains 68 mg of the progestin 
and releases ENG 60-70 mcg/day. DES, sold under the brand names Cerazette® and Micertte®, 
is used in birth control pills for women. The daily-used tablets contain 0.15 mg of DES. DNG is 
also used in contraceptive pills and is sold under the brand name Natazia® and Qlaira®. The 
medication is available both alone and in combinations with estrogens. The progestin-only tablets 
contain 2 mg of DNG. UPA is a medication used for emergency contraception. It is sold under the 
brand name Ella®. As emergency birth control product, it should be used within 120 hours of sex. 
A vaginal ring, releasing 2.5 mg/d UPA, is currently under a Phase II clinical trial. The four 
progestins, chosen in this project, also span different progestin generations. (Table 1.3.3.1) 
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 Table 1.3.3.1. Summarized table of four progestins used in this work.  
* Clinical daily doses of each progestin were calculated based on other contraceptive products. 
Agent Generation LogP Target Clinical Dose*  
(mg/1”X2” film) 
Etonogestrel 
(ENG) 
3  
(LNG derivative) 
4.2 0.06 
Desogestrel 
(DES) 
3 
(LNG derivative) 
6.6 0.15 
Dienogest (DNG) 4 (estrane) 1.9 2 
Ulipristal Acetate 
(UPA) 
N/A 
(Selective PR modulators) 
4.5 3 
 
Other than APIs, film formulations usually include water-soluble polymers, plasticizers, 
fillers, colorants and flavoring agents (54). Water soluble polymers should be non-toxic; non-
irritant; possess good wetting, spreadability, peelability; exhibit moderate mechanical properties; 
inexpensive to manufacture (58). Plasticizers are added to provide flexibility and pliability (54). 
Other excipients can be included for better patient’s compliance. Among all the excipients, the 
type of polymer and its molecular weight dramatically influences the properties of the film (50). 
Polyacrylates, polyethylene glycol, polyvinyl alcohol (PVA), and cellulose derivatives are the 
polymers commonly used in vaginal films (59). Our lab has already developed a solvent-cast (SC) 
polymeric vaginal film platform (1). This PVA-based formulation was originally used for vaginal 
delivery of dapivirine (DPV), a potent anti-retroviral molecule. This quick dissolve film provides 
rapid drug release, lacks toxicity to the innate microflora, maintains stability and retains bioactivity 
of APIs (52). Therefore, this SC platform was chosen as a platform incorporation of the progestins. 
Hence, the goal of this project was to investigate the feasibility of application of the SC platform 
for progestin drugs.   
Technological characterization of developed films on various esthetic, chemical, physical, 
mechanical, and performance parameters was tested (1, 60). One paper (50) summarized all the 
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characterizations for vaginal films in one table. Appearance, color, and transparency are the main 
characteristics to be evaluated for films. Thickness and surface morphology are physical 
parameters that characterize vaginal films. Controlling of the water content of films is essential, as 
water content impacts mechanical properties of the film. In addition, high water content might 
contribute to microbial growth over time, low water content might affect disintegration (1, 61). 
Drug content, content uniformity, in vitro drug release and film pharmacokinetics are highly 
dependent on film chemical and physical properties (61). One behavioral clinical study (62) asked 
participants to compare a variety of vaginal films using a set of in mano perceptibility survey items. 
Women most frequently preferred vaginal films to be thin and smooth and translucent. The size of 
films mattered to some women, but the preferred size differed individually. In conclusion, physical 
properties, including thickness, weight, puncture strength, water content, disintegration time and 
drug content should be tested for controlling the product quality. These attributes can be defined 
prior to product development as Target Product Specifications.  
Our goal is to demonstrate the capacity of this film platform for application to vaginal 
delivery of progestins. To achieve this goal, we propose that the platform can incorporate a range 
of progestins and generate polymeric vaginal films with desired physical properties.  
 21 
2.0  MATERIALS AND METHODS 
2.1 MATERIALS 
Desogestrel (DES) was obtained from Tokyo Chemical Industry company (Japan). Etonogestrel 
(ENG), dienogest (DNG) and ulipristal acetate (UPA) were obtained from LGM Pharma (Erlanger, 
KY, US). Ethanol (HPLC grade), acetonitrile (ACN, HPLC grade), trifluoroacetic acid (TFA) were 
obtained from Fischer Scientific (Pittsburgh, PA, US). Polyvinyl alcohol (PVA 40-88), propylene 
glycol and glycerin were purchased from Spectrum (Gardena, CA, US). Creamophor (Kolliphor® 
RH 40) was purchased from Sigma-Aldrich (St. Louis, MO, US). Polyethylene glycol (PEG 8000) 
and hydroxypropyl methylcellulose (HPMC E5) were obtained from Dow Chemical Company 
(Midland, MI, US). All other chemicals were analytical grade. The filters (Millex®-LG low 
protein binding hydrophilic LCR(PTFE) membrane) were obtained from Sigma-Aldrich.  
Ultrapure water was obtained from an in-house Milli-Q® water purification system (Millipore 
Sigma Advantage A10). 
2.2 METHODS 
2.2.1 Film formulation 
Formulation was adapted based on an established platform(54). Polyvinyl Alcohol (PVA) and 
Hydroxypropyl Methylcellulose (HPMC E5) were selected as film-forming polymers. Ethanol was 
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added as solubilizing/dispersing aid. Other excipients, polyethylene glycol (PEG) 8000, propylene 
glycol, and glycerin were also composed in the formulation as described in Table 2.2.1.1. 
 
Table 2.2.1.1. Formulation for Progestin Films. 
Ingredient Role 
Polyvinyl Alcohol 
(PVA 40-88) 
Film Forming 
Hydroxypropyl Methylcellulose 
(Methocel E5) 
Film Forming  
Polyethylene Glycol (PEG) 8000 Disintegration Agent 
Propylene Glycol/ Glycerin Plasticizer/Dispersing Aid 
Drug Effective Agent 
Ethanol Solubilizing/Dispersing Aid 
 
The progestin film was prepared by the solvent-cast (SC) method. Briefly, PVA was 
dissolved in Milli-Q water, and to expedite dissolution, the mixture was placed in a hot water bath 
(90℃) until the PVA was completely hydrated. HPMC E5 was then slowly added into the PVA 
solution with moderate stirring using an overhead mixer. After the polymer solution became 
uniform and homogenous, the plasticizer was added. The mixture was allowed to stir overnight in 
order to remove any entrapped air bubbles. In the end, the progestin dissolved in ethanol was added. 
The mixture was stirred for no less than three hours to obtain a uniform polymer solution. The 
solution was then cast onto a polyester substrate attached to the hot surface of an automatic film 
applicator (Elcometer 4340 Automatic Film Applicator) using a 4-inch or 8-inch doctor blade. The 
solvent evaporated after 15 minutes, leaving a thin layer of film. The film sheet was removed from 
the polyester substrate and cut into 1”X2” rectangle pieces using a die press. The films were 
separately packed into aluminum pouches. 
 23 
Two dosing levels for each progestin were manufactured, clinical dose films and equal 
dose films. Clinical daily doses were meant to reflect the doses which are available clinically. The 
clinical doses were calculated based on products which are on the market. Progestin films 
incorporated with clinical doses were named as clinical dose films; To better investigate whether 
the progestin impacts the film, a same dose was chosen for all progestins. The polymeric films 
incorporated with the equal dose were named as equal dose films.   
2.2.2 Film characterizations 
2.2.2.1 Weight and thickness 
The film weight was measured by scientific balance (Mettler Toledo, XS205); The film thickness 
was measured at three different locations (two corners on one diagonal line and center) by 
thickness gauge (Mitutoyo, Absolute). 
2.2.2.2 Water content 
The water content was measured by Karl-Fischer Titer apparatus (Metrohm, 890 Titrando) in 
accordance with the titration method specified by the manufacturer.  
2.2.2.3 Mechanical properties 
Puncture strength and disintegration time of the film were tested using a Texture Analyzer (Texture 
Technologies, TA. XT Plus). Briefly, to test the puncture strength, the film was fixed on a film 
extensibility rig with only a flat round surface of the film was exposed. A probe was used at a 
perpendicular angle with increasing force. The analyzer recorded the force as puncture force when 
the film was penetrated. Puncture strength (kg/mm) is puncture force (kg) divided by the film 
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thickness (mm); For determination of the disintegration time, the film was fixed on the rig in the 
same way as mentioned above. 15µl Milli-Q water was first applied on the film, and then a probe 
was used at a perpendicular angle with a constant force. The apparatus measured the time it took 
for the probe penetrated the film, named as the disintegration time. 
2.2.2.4 Drug content 
The drug content was analyzed by High Performance Liquid Chromatography (HPLC) system. 
The film was fully dissolved in 4 ml of 50% ACN solution (in MilliQ water) via a vortex mixer. 
After sitting still for 4 hours or more, the upper clear solution was extracted. The solution was 
filtered and aliquoted for HPLC analysis. The HPLC system (Thermo Scientific, Dionex UltiMate 
3000) equipped an auto injector, a quaternary pump, and a diode array detector was used. 
Chromeleon 7 Software was used for controlling the HPLC system, as well as calculating the drug 
content based on the total peak area. A C18 reverse phase column (Waters, xBridge C18, 5µm, 
2.1X50mm) was used for separating the compound of interest at room temperature. The mobile 
phase consisted of (A) 0.1% TFA in MilliQ water and (B) 0.05% TFA in ACN using a gradient 
elution at a flow rate of 1.0 ml/min. The DES was determined by Ultra-Violet (UV) detection at 
210 nm, the ENG at 242 nm, the DNG at 275 nm, the UPA at 275 nm. 
2.2.2.5 Target product specifications 
Physical properties, including thickness, weight, puncture strength, water content, disintegration 
time and drug content were selected as Target Product Specifications (Table 2.2.2.5.1). The 
specifications were used for stability study of the progestin film.  
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Table 2.2.2.5.1 Summarized table of specifications for vaginal films.  
Test Specification 
 Weight 80 -120% of the value at Time 0 
Thickness 80 -120% of the value at Times 0 
Puncture Strength 80 -120% of the value at Times 0 
Water Content Water Content < 10% 
Disintegration No more than (NMT) 250 seconds 
Drug Content  80 -120% of the value at Times 0 
 
2.2.3 Short-term stability study 
After film manufacture, each film was separately packaged in an aluminum foil pouch. For each 
progestin group, films were randomly selected and stored under two conditions ([25℃/65% RH]; 
[40℃/75% RH]). The stability of the film was monitored for three months (Times 0; 1 week; 2 
weeks; 1 month; 2 months; 3 months). At each time point, the physical characterizations and drug 
content were determined for all groups. 
2.2.4 Dissolution study 
To determine the kinetics of drug release, an in vitro release study was conducted using a USP 1 
apparatus (Distek dissolution system 2100C). In this method, the film was placed in a 40-mesh 
standard basket, which was fully emerged in a certain amount of 1% Cremophor® solution (1g 
Cremophor® in 100 mL Milli-Q Water). The baskets were set to rotate at 100 rpm for 6 hours. 0.5 
mL of the media was sampled at each time point (15 minutes; 30 minutes; 1 hour; 2 hours; 3 hours; 
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4 hours; 5 hours; and 6 hours), and 0.5 mL of the fresh 1% Cremophor® solution was replaced at 
each time point. The study design is shown in Table 2.2.4.1. 
The drug concentration at each time point was tested using HPLC. The cumulative released 
drug amount was calculated. The theoretical drug content was estimated by the film weight and 
the average ratio of drug content/ film weight (w/w, %). The percentage of released drug was 
calculated by the accumulated released drug amount/ the theoretical drug content. 
Table 2.2.4.1. Summary of the Dissolution Study for Contraceptive Films.  
*Sink condition media volume is at least 3 times greater than the volume present in the saturated solution. 
Dissolution Study for Contraceptive Films 
API Name Log P 
Solubility 
(ug/mL) 
Clinical Dose 
(mg/Film) 
Sink Condition 
Media Volume* (mL) 
DNG 1.9 49.84 2 150 
ENG 4.2 93.51 0.06 5 
UPA 4.5 86.88 3 150 
DES 6.6 716.75 0.15 5 
 
2.2.5 Statistical analysis 
For comparison of the progestin film at two dose levels, statistical analysis was performed using a 
two-tailed Student’s t-test. A P-value < 0.05 was considered statistically significant.   
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3.0  RESULTS 
3.1 THE FILM PLATFORM CAN PRODUCE CLINICAL DOSE PROGESTIN 
FILMS 
These progestins have already been used in products which are on the market. To demonstrate that 
the film platform can incorporate the progestins, we would like to use the doses which are used 
clinically. These clinical doses were calculated based on the approved length of the product and 
the amount of progestin incorporated in products respectively, as shown in Table 3.1.1. The 
physical characterizations were tested for all four films. For each physical characterization, three 
films were randomly selected. All the physical characterizations and drug contents are shown in 
Table 3.1.2. The target dose (w/w) in Table 3.1.2 was the clinical dose (mg/film) divided by the 
average film weight (mg/film). 
Despite of the different doses, all four progestin films can be manufactured with targeted 
dosing levels.  
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Table 3.1.1. Summary of progestin used in clinical dose polymeric films 
Progestin Log P 
Clinical Dose 
(mg/film) 
Etonorgestrol 
(ENG) 
4.2 0.06 
Desogestrel 
(DES) 
6.6 0.15 
Dienogest 
(DNG) 
1.9 2 
Ulipristal Acetate 
(UPA) 
4.5 3 
 
 
Table 3.1.2. Summary of the clinical dose progestin films’ physical characterizations.  
Data was presented as Mean ± SD. N=3 for each group. 
 
 
DNG
(XT-1-137)
ENG
(XT-1-159)
UPA
(XT-1-161)
DES
(XT-1-139)
Log P 1.9 4.2 4.5 6.6
Weight (mg) 178.14±17.22 182.51±16.00 139.54±17.19 131.34±21.34
Thickness (mm) 0.13±0.01 0.13±0.02 0.11±0.01 0.11±0.02
Puncture Strength 
(Kg/mm)
14.25±2.06 15.47±1.39 13.62±0.47 14.62±1.40
Water Content (%) 4.46±0.32 2.19±0.13 1.55±0.06 4.01±0.12
Disintegration (sec) 151.76±21.16 244.70±28.33 123.96±5.36 80.88±43.18
Target Dose
(w/w; µg/mg Film)
12.30 0.40 18.40 0.90
Assayed Dose
(w/w; µg/mg Film)
14.00±0.30 0.50±0.00 23.80±1.50 1.10±0.00
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3.2 THE FILM PLATFORM CAN PRODUCE EQUAL DOSE PROGESTIN FILMS 
In order to further investigate the progestin’s effects on physical properties of the film, this panel 
of progestins were incorporated in films at the same dose. These progestin films with the same 
dosing level were named as the equal dose progestin films. This dose was chosen based on the 
mid-range clinical dose, which is the clinical dose of DES. Table 3.2.1 shows the lipophilicity and 
dose of progestins. All the physical characterizations and drug contents are shown in Table 3.2.2. 
The target dose (w/w) in Table 3.2.2 was the equal dose (mg/film) divided by the average film 
weight (mg/film). For each physical characterization, three films were randomly selected. 
 
Table 3.2.1. Summary of the progestins used in equal dose polymeric films. 
 
Progestin Log P Equal Dose (mg/film) 
Etonorgestrol 
(ENG) 
4.2 0.15 
Desogestrel 
(DES) 
6.6 0.15 
Dienogest 
(DNG) 
1.9 0.15 
Ulipristal Acetate 
(UPA) 
4.5 0.15 
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Although the progestins have various lipophilicities, the equal dose progestin films can be 
produced. All four progestin films are at the same drug loading level. In addition, the equal dose 
films have similar physical characterizations—weights, thickness, water content, puncture strength, 
and disintegration time. The data demonstrate that the progestin film platform can produce equal 
dose progestin films with similar physical properties. 
Table 3.2.2. Summary of the equal dose progestin films` physical characterizations. 
Data was presented as Mean ± SD. N=3 for each group. 
 
 
 
 
DNG
(XT-1-67-2)
ENG
(XT-1-83-2)
UPA
(XT-1-82-2)
DES
(XT-1-103)
Log P 1.9 4.2 4.5 6.6
Weight (mg) 164.34±12.76 152.67±10.72 162.47±14.70 174.14±12.96
Thickness (mm) 0.11±0.01 0.10±0.01 0.11±0.01 0.13±0.01
Puncture Strength 
(Kg/mm)
25.23±0.97 21.20±1.44 16.88±1.90 15.21±0.11
Water Content (%) 2.09±0.04 1.56±0.20 1.88±0.04 2.06±0.12
Disintegration (sec) 142.33±31.74 125.25±15.38 127.54±27.34 165.84±18.61
Target Dose
(w/w; µg/mg Film)
0.90 0.90 0.90 0.90
Assayed Dose
(w/w; µg/mg Film)
0.70±0.10 0.70±0.00 0.80±0.09 0.80±0.00
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3.3 PROGESTIN FILMS OF TWO DOSING LEVELS HAVE DIFFERENT 
PHYSICAL CHARACTERIZATIONS 
For DNG, ENG, and UPA, polymeric films were manufactured at two dosing levels. To study 
whether the amount of progestin impacts the physical characterizations of the films, we compared 
DNG films, ENG films, and UPA films across two dosing levels respectively. Physical 
characterizations of DNG films are shown in Figure 3.3.1. Physical characterizations of ENG films 
are shown in Figure 3.3.2. Physical characterizations of UPA films are shown in Figure 3.3.3.  
Compared across the two dosing levels, significant differences were observed on puncture 
strength and water content for DNG, ENG and UPA films (p<0.05). All three clinical dose films 
had lower puncture strength. For DNG and ENG films, clinical dose films had higher water content. 
The ENG clinical dose films had significantly longer disintegration time (p<0.05), compared to 
the ENG equal dose films. Other physical characterizations, such as weight and thickness, 
remained the same for progestin films of two dosing levels.  
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Figure 3.3.1 Physical characterizations of DNG films at two dosing levels.  
A. Weight (mg) was measured by scientific balance; B. Thickness (mm) was measured by thickness gauge; 
C. Puncture strength (kg/mm) was analyzed by Texture Analyzer at each time point. The puncture strength 
(kg/mm) was the puncture force (kg) divided by the film thickness (mm); D. Water content (%) was measured 
by Karl-Fisher Titer apparatus; E. Disintegration time (sec) was analyzed by Texture Analyzer. Significant 
differences were observed for puncture strength and water content. Data was presented as Mean ± SD. N=3 
for each group. * P-value < 0.05. 
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Figure 3.3.2 Physical characterizations of ENG films at two dosing levels.  
A. Weight (mg) was measured by scientific balance; B. Thickness (mm) was measured by thickness gauge; 
C. Puncture strength (kg/mm) was analyzed by Texture Analyzer at each time point. The puncture strength 
(kg/mm) was the puncture force (kg) divided by the film thickness (mm); D. Water content (%) was measured 
by Karl-Fisher Titer apparatus; E. Disintegration time (sec) was analyzed by Texture Analyzer. Significant 
differences were observed for puncture strength, water content and disintegration time. Data was presented 
as Mean ± SD. N=3 for each group. * P-value < 0.05. 
 
 
 
E
qu
al
  D
os
e 
Fi
lm
C
lin
ic
al
 D
os
e 
Fi
lm
0
50
100
150
200
250
Weight for ENG Films
W
e
ig
h
t 
(m
g
)
E
qu
al
  D
os
e 
Fi
lm
C
lin
ic
al
 D
os
e 
Fi
lm
0.00
0.05
0.10
0.15
0.20
Thickness for ENG Films
T
h
ic
k
n
e
s
s
 (
m
m
)
E
qu
al
  D
os
e 
Fi
lm
C
lin
ic
al
 D
os
e 
Fi
lm
0
5
10
15
20
25
Puncture Strength for ENG Films
P
u
n
c
tu
re
 S
tr
e
n
g
th
 (
k
g
/m
m
)
E
qu
al
  D
os
e 
Fi
lm
C
lin
ic
al
 D
os
e 
Fi
lm
0.0
0.5
1.0
1.5
2.0
2.5
Water Content for ENG Films
W
a
te
r 
C
o
n
te
n
t 
(%
)
E
qu
al
  D
os
e 
Fi
lm
C
lin
ic
al
 D
os
e 
Fi
lm
0
100
200
300
Disintegration Time for ENG Films
D
is
in
te
g
ra
ti
o
n
 T
im
e
 (
s
e
c
)
*
*
A B C
D E
*
 34 
 
Figure 3.3.3 Physical characterizations of UPA films at two dosing levels. 
A. Weight (mg) was measured by scientific balance; B. Thickness (mm) was measured by thickness gauge; 
C. Puncture strength (kg/mm) was analyzed by Texture Analyzer at each time point. The puncture strength 
(kg/mm) was the puncture force (kg) divided by the film thickness (mm); D. Water content (%) was measured 
by Karl-Fisher Titer apparatus; E. Disintegration time (sec) was analyzed by Texture Analyzer. Significant 
differences were observed for puncture strength and water content. Data was presented as Mean ± SD. N=3 
for each group. * P-value < 0.05. 
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3.4 THE CLINICAL DOSE PROGESTIN FILMS REMAIN STABLE FOR AT 
LEAST THREE MONTHS 
The clinical dose progestin films were randomly divided into two groups, stored under two 
conditions ([25℃/65% RH]; [40℃/75% RH]) as per ICH guidelines. The films were monitored 
for short-time stability (3 months). At each time point (Time 0; 1 week; 2 weeks; 1 month; 2 
months; 3 months), films were analyzed for physical characterizations. The data of films’ weight 
is presented in Figure 3.4.1; Thickness in Figure 3.4.2; Puncture strength in Figure 3.4.3; Water 
content in Figure 3.4.4; Disintegration time in Figure 3.4.5; Drug content in Figure 3.4.6. 
For all four progestin films, the film weights, thickness and puncture strength remained 
constant through three months. The water content remained below 10% at all time. The 
disintegration time remained less than 250 seconds. Based on the target product specifications 
(Table 2.2.2.5.1), these physical properties were all stable through three months. For DNG, ENG 
and UPA films, the drug content remained between 80% - 120% for three months. For DES films, 
drug content remained constant over a 1-month period but was significantly decreased (p<0.05) at 
three months. In addition, the films were stored under two different conditions, 25°C/65%RH and 
40°C/75%RH. No difference on physical characterizations was observed between films stored 
under these two conditions. Similarly, all the drug contents of the progestin films were not affected 
by the temperature and humidity. 
The developed film platform can incorporate all four progestins with consistent physical 
characterizations through 3 months, regardless of the various physicochemical properties. The data 
illustrate that the SC film platform can produce stable progestin films. 
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Figure 3.4.1 Weights (mg) of four progestin films stored under two conditions in 3 months.  
A. DNG films; B. DES films; C. ENG films; D. UPA films. The weight (mg) was measured by an analytical 
balance at each time point. Data was presented as Mean ± SD. N=3 for each group. 
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Figure 3.4.2 Thickness (mm) of four progestin films stored under two conditions in 3 months.  
A. DNG films; B. DES films; C. ENG films; D. UPA films. The thickness (mm) was analyzed by thickness 
gauge at each time point. Data was presented as Mean ± SD. N=3 for each group. 
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Figure 3.4.3 Puncture strength (kg/mm) of four progestin films stored under two conditions in 3 months. 
A. DNG films; B. DES films; C. ENG films; D. UPA films. The puncture force (kg) was analyzed by Texture 
Analyzer at each time point. The puncture strength (kg/mm) was the puncture force (kg) divided by the film 
thickness (mm). Data was presented as Mean ± SD.  N=3 for each group. 
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Figure 3.4.4 Water Content (%) of four progestin films stored under two conditions in 3 months. 
A. DNG films; B. DES films; C. ENG films; D. UPA films. The water content (%) was analyzed by Karl-
Fisher Titer apparatus at each time point. The red dashed lines indicate the Target Product Specification. All 
water content was < 10%. Data was presented as Mean ± SD. N=3 for each group. 
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Figure 3.4.5 Disintegration time (sec) of four progestin films stored under two conditions in 3 months. 
A. DNG films; B. DES films; C. ENG films; D. UPA films. The disintegration time (sec) was analyzed by 
Texture Analyzer at each time point. The red dashed lines indicate the Target Product Specification. All 
disintegration time was NMT 250 seconds. Data was presented as Mean ± SD. N=3 for each group. 
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Figure 3.4.6 Drug content (w/w) of four progestin films stored under two conditions in 3 months. 
A. DNG films; B. DES films; C. ENG films; D. UPA films. The drug amount was analyzed by HPLC at each 
time point. Drug content (w/w) was the drug amount (mg) divided by the film weight (mg). The red dashed 
lines indicate the targeted drug content (w/w) respectively (A: 0.0123; B: 0.0009; C: 0.0004; D: 0.0184). 
Data was presented as Mean ± SD. N=3 for each group. For DNG, ENG and UPA films, drug content 
remained between 80% -120% through 3 months. For DES films, the drug content at 3 months was 
significantly different compared to that at 1 month. * P-value < 0.05. 
 
  
0.0000
0.0050
0.0100
0.0150
0.0200
Time 0 1W 2W 1M 2M 3M
D
r
u
g
 C
o
n
te
n
t 
(w
/w
)
Time
Drug Content (w/w)  for DNG Films
DNG Film [25C/ 65% RH] DNG Film [40C/ 75% RH]
A
0.0000
0.0002
0.0004
0.0006
0.0008
0.0010
Time 0 1W 2W 1M 2M 3M
D
r
u
g
 C
o
n
te
n
t 
(w
/w
)
Time
Drug Content (w/w)  for ENG Films
ENG Film [25C/ 65% RH] ENG Film [40C/ 75% RH]
C
0.0000
0.0002
0.0004
0.0006
0.0008
0.0010
Time 0 1W 2W 1M 2M 3MD
r
u
g
 C
o
n
te
n
t 
(w
/w
)
Time
Drug Content (w/w)  for DES Films
DES Film [25C/ 65% RH] DES Film [40C/ 75% RH]
B
*
0.0000
0.0100
0.0200
0.0300
0.0400
Time 0 1W 2W 1M 2M 3MD
r
u
g
 C
o
n
te
n
t 
(w
/w
)
Time
Drug Content (w/w) for UPA Films
UPA Film [25C/ 65% RH] UPA Film [40C/ 75% RH]
D
 42 
3.5 PROGESTINS DO NOT AFFECT THE RELEASE PROFILE OF THE 
POLYMERIC VAGINAL FILMS 
The in vitro drug release profile is an important specification for this film platform. Because 
intended formulation was fast dissolve films (1), incorporation of hydrophobic drugs should not 
alter the release profile. To determine the release profile for the four progestin films, an in vitro 
dissolution study was performed using a USP 1 basket method. The clinical dose films were chosen 
for the study. For each group, three films were randomly selected. The drug content of the samples 
was tested by HPLC. The dissolution results are shown in Figure 3.5.1.  
 
Figure 3.5.1 Dissolution curves of four progestin films in 6 hours.  
In vitro dissolution study was conducted using a USP 1 apparatus (Distek dissolution system). Sink 
conditions were maintained for all films. 1% (w/v) Cremophor solution was used as dissolution media. The 
baskets were set to rotate at 100 rpm for 6 hours. 0.5 mL of the media was sampled at each time point (15 
minutes; 30 minutes; 1 hour; 2 hours; 3 hours; 4 hours; 5 hours; and 6 hours), and 0.5 mL of the fresh 1% 
Cremophor solution was added. The accumulated drug amount was calculated at each time point.  
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Within 15 minutes, at least 70% of the drug was released from the film. After 30 minutes, 
the released drug amounts of ENG, DNG and UPA films plateaued. For DES and ENG films, the 
drug amounts both reached 100% within 1 hour. However, the cumulated drug amount of DES 
decreased slightly (around 10%) after 2 hours. For UPA films, the released drug amounts 
accumulated above 90% in 6 hours. For DNG films, the accumulated drug amount was 84% and 
remained around 80%. These dissolution profiles followed the same fast release trend, which was 
expected as the films used in this study were designed to be fast-dissolved films. The various 
physiochemical properties of these progestins did not affect the drug being quickly released from 
the film. 
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4.0  DISCUSSION 
Reducing unintended pregnancy has remained to be one of the most important reproductive health 
goals identified by the United States Departments of Health and Human Services since last century 
(2). Even with various contraceptive options existing globally, a considerable portion of pregnancy 
is unintended (unwanted or mistimed). To this end, novel drug delivery systems, such as polymeric 
vaginal films, need to be developed for incorporation of contraceptive agents. Beyond that, 
polymeric vaginal films can provide a platform for design of combination products of 
contraceptive agents and anti-retroviral agents to achieve preventions of both unintended 
pregnancy and HIV infection. The first step of this goal is to manufacture stable polymeric films 
containing hormones, specifically in this project, progestins.   
One behavioral clinical study (62) asked participants to compare a variety of vaginal films. 
Women mostly frequently preferred vaginal films to be thin, smooth, and translucent. The size of 
films did matter to some women, but the result was debatable. Some women preferred 2”X2” 
square films as they thought it might be easier to insert and cover more vaginal area so that it 
would work better. Others argued that smaller sizes were more discreet and would not be felt inside 
the vagina, as 2”X2’’ square films might be too obvious. In this project, we chose to manufacture 
smooth, translucent rectangular films of a 1”X2” size. 
Film formulations usually comprise water-soluble polymers, plasticizers, fillers, colorants 
and flavoring agents (54). Water soluble polymers should be non-toxic; non-irritant; possess good 
wetting, spreadability, peelability; exhibit moderate mechanical properties; and be inexpensive to 
manufacture (58). Plasticizers are added to provide flexibility and pliability (54). Disintegrants can 
be used to provide rapid film disintegration once in touch with fluids. Other excipients may be 
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included to enhance patient compliance. The formulation used in these studies was adapted from 
the formulation previously developed for dapivirine (1). All excipients in this formulation have a 
history of use and were found to be safe. Polyvinyl alcohol (PVA) is a polymer base which is used 
in several currently marketed vaginal film products (1). This film combines PVA with 
hydroxypropyl methylcellulose (HPMC) as a copolymer. The ratio of polymers used was based on 
their ability to improve film properties, such as tensile strength, elongation, toughness, and elastic 
modulus (54). In addition, given the hydrophobic nature of progestin and hydrophilic nature of the 
polymer base, progestin exists as a dispersion in the film product. Therefore, the polymer 
concentration is essential to provide adequate viscosity to maintain the drug dispersion during the 
manufacturing process. However, the high viscosity of polymer solution can result in entrapped 
air during film manufacture, which will affect the physical properties of the film. To this end, 
sedimentation studies are required to ensure adequate dispersion of progestin in the polymeric 
solution through the film product manufacturing process.  
Propylene glycol and glycerin were used as plasticizers in the formulation. The plasticizers 
enhance film flexibility, mechanical properties and softness. Moreover, propylene glycol was used 
in the formulation to facilitate the dispersion of the hydrophobic drug (1). Since dapivirine has 
similar lipophilicity (logP=5.3) as the most hydrophobic progestins used in this project (logP 
ranging from 1.9 to 6.6), it was initially attempted to utilize propylene glycol as a dispersant for 
the progestin prior to addition into the polymer solution. Unfortunately, this process resulted in 
drug content of less than 74%. The limited drug incorporation illustrated that propylene glycol was 
not an adequate dispersant for progestin. Ethanol, a commonly-used solvent for hydrophobic drugs 
(63), was then evaluated as a dispersing/dissolving aid for progestins. Incorporation of ethanol 
increased drug content to greater than 80%. Based on this finding, ethanol was incorporated to 
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avoid drug precipitation. The good miscibility of ethanol with water also facilitated formation of 
a homogenous solution, resulting in better uniformity of drug disposition in films.  
To study whether the type of progestin impacts the physical characterization of the film, 
films were manufactured at an equal dose level (Table 3.2.1). Despite their hydrophobic chemical 
nature, all progestins could be successfully manufactured into solvent-cast films as expected 
(Table 3.2.2). This demonstrated the wide versatility of this aqueous-based film platform. When 
the progestins were incorporated into the film at the same level (Table 3.2.2), no differences were 
observed in film weight, thickness or water content (p>0.05). Comparisons across this panel of 
progestin films at an equal dosing level demonstrated that progestin incorporation did not impact 
physical characterizations of the film. All film properties tested met the established primary target 
product specifications (Table 2.2.2.5.1).  
To investigate the impact of progestin amount on physical characterizations of the film, we 
compared the films at two dosing levels (Figure 3.3.1, Figure 3.3.2 and Figure 3.3.3). The clinical 
dose films had lower puncture strength (p<0.05) as well as higher water content (p<0.05) for ENG 
and DNG films. It was reported that the type and amount of API in the film may impact physical 
properties, such as mechanical strength and swelling (64). We also considered that there may be a 
correlation between high water content and low puncture strength in these films. Water could act 
as a plasticizer (65). The water in the film may compete with API for hydrogen bonding with 
polymers (66). Given the hydrophilic nature of the polymer base (PVA) and the hydrophobic 
nature of progestins, polymers had a decreased ability to form hydrogen bonds when more 
progestin was included in the formulation. Thus, polymers have to form hydrogen bonds with 
water. The lack of hydrogen bonds will form a weak network structure (67). Therefore, an 
increased amount of progestin resulted in high water content and low puncture strength. In addition, 
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the clinical dose film was manufactured on a larger scale (five times of the scale of equal dose 
films). In a large-scale manufacturing process, more ethanol was used for dispersing the 
hydrophobic progestin. One study (68), analyzing hydrophilic zein (a class of protein found in 
maize) films made by either acetone or ethanol, indicated that ethanol affected mechanical 
properties of the film. Therefore, the different amounts of ethanol may also contribute to the 
differences in physical properties, such as puncture strength, water content and disintegration time.  
The stability study demonstrated that the clinical films were stable for at least three months 
and were not impacted by temperature. Based on target product specifications (Table 2.2.2.5.1), 
physical characterizations of films, including weight (Figure 3.3.1), thickness (Figure 3.3.2), water 
content (Figure 3.3.4) and disintegration time (Figure 3.3.5), remained stable. For ENG, DNG and 
UPA films, drug content remained between 80% - 120% of Time 0. However, a decrease in drug 
content (Figure 3.3.6 B) was observed for DES films (p<0.05). DES is the pro-drug of ENG. It can 
be rapidly transformed into one of its metabolites, ENG (etonogestrel/ 3-keto-desogestrel), by 
CYP3A4 (69). In addition, DES is susceptible to oxidation and it is reported that DES is 
incompatible with strong oxidizing agents (70). Compared to other hormones used in that study 
(EE and LNG), DES was easily degraded under 1% hydrogen peroxide, while others remained 
stable (71). Therefore, this decrease in drug content could be due to the oxidation of DES. To stop 
the degradation of DES, anti-oxidants can be added in the formulation (72). In contrast, ENG, 
UPA, and DNG all have a keto group on C3 position which is a more stable functional group 
(Appendix A). Ketone is a well-known, stable form. Particularly in these three progestins, the keto 
form can share the Pi bond with the nearby alkane group (carbon-carbon double bond). Also, as a 
hydrogen bond acceptor, the 3-keto group might increase the stability of ENG, UPA, and DNG. 
Therefore, no decrease was observed in drug content for these three progestin films. Moreover, no 
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differences in drug content were observed between progestin films stored when stored at either of 
the two test conditions.   
To appropriately determine if developed vaginal products will effectively distribute drug 
to target tissues and the systemic compartment, two critical factors must be considered. The first 
being the efficiency on rate of drug release from the vaginal product and the second being the 
ability for drug to permeate the mucosal epithelium (73). The primary methods in a preclinical 
study to evaluate these critical components of delivery are dissolution and ex vivo permeability 
assessments. Dissolution testing was conducted for the progestin films developed. In this project, 
we first demonstrated that the polymeric films were fast-dissolving films, which was consistent 
with our hypothesis. According to set Target Product Specifications, the fast-dissolving films 
should release at least 80% of the drug within the first 30 minutes (74). In vitro dissolution study 
showed that all the four progestin films released over 80% of the drug within the first 15 minutes 
(Figure 3.4.1), indicating that progestin could be quickly released from the film. However, 
differences can be observed among these release profiles. The cumulated drug amount of DES 
decreased after 2 hours. This phenomenon may be due to the instability of DES in the medium 
(w/v 1% Cremophor solution). Cremophor is polyethoxylated castor oil, commonly used for 
poorly-water soluble drugs (75). Because of the hydrophobic nature of some progestins, it was 
necessary to use Cremophor in the dissolution medium to maintain sink conditions throughout the 
study. However, Cremophor would not be a biologically relevant condition. One study (76) found 
that it has systemic toxicity, as Cremophor caused oxidative damage to red blood cells. Another 
study (65) also demonstrated the oxidative nature of Cremophor. As mentioned above, DES is 
susceptible to oxidation. The Cremophor in the dissolution media may cause oxidation of DES, 
leading to the decrease of cumulative drug amount.  
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Although progestins are Biopharmaceutical Class System (BCS) II drugs, which have good 
permeability, the stratified multilayer vaginal epithelium may represent a barrier for progestin 
permeation. For this reason, in addition to the dissolution study, the permeability of progestin in 
both the formulated and unformulated state should be evaluated using an excised cervical tissue to 
establish the permeability profile for progestins.  
Physiological factors will also affect the absorption of progestin, including the thickness 
of epithelium layer, the volume of vaginal fluid, and alteration of vaginal pH. These factors vary 
individually, resulting in different contraceptive effects on different patients. In order to minimize 
the individual differences and achieve more consistent contraceptive effects, the progestin dose in 
the film is essential. The doses that we determined in this project as clinical doses were calculated 
based on products on the market. Besides UPA, which clinical dose was calculated based on a 
vaginal ring, other clinical doses were calculated based on non-intravaginal drug delivery systems. 
For example, ENG dose was based on an implant; DNG and DES doses were based on pills. Indeed, 
different administration routes will result in pharmacokinetics differences. Compared to oral drug 
delivery system, such as pills, vaginal delivery offers certain advantages, such as avoidance of gut 
and hepatic first-pass metabolism (73). One recent study indicated that the mucoadhesive tablets 
had higher mean residence time (MRT) in the blood and higher bioavailability with oral 
progesterone administration (77). After implant insertion, ENG is rapidly absorbed into the 
circulation and becomes almost 100% bioavailable (78). Compared to this subcutaneous drug 
delivery system, vaginal delivery shows a potential limitation in absorption and distribution, 
because progesterone can accumulate in the uterine tissue after vaginal application (79). Thus, it 
is difficult to quantitatively estimate the distribution of a drug after an intravaginal administration 
based on available data from non-vaginal drug delivery systems for contraception. Therefore, in 
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future studies, the effective clinical doses will need to be established through established in vivo 
animal studies. 
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5.0  LIMITATION   
In order to incorporate all the progestins in this SC platform, ethanol was used as 
dispersing/dissolving agent. Ethanol belongs to Class 3 solvents (solvents with low toxic potential). 
For a Class 3 solvent, the allowable limit of residual amount in the final product is 0.5%. Therefore, 
a methodology of testing residual ethanol in the film must be developed. In addition, progestins, 
such as DES, had limited solubility in ethanol. Other solvents, such as ethyl ether and acetone, 
should be considered and analyzed for their compatibility with progestins (70). Further, 
undissolved progestins may exist in the film in either the crystalline or amorphous state (80). It 
was reported that crystal form may impact the drug solubility (81). Polymorphs can also impact 
the bioavailability and stability of poorly soluble drugs (82). The crystal structure of progestins in 
the film should be analyzed by X-ray crystallography or differential scanning calorimetry.  
Given the hydrophilic nature of the polymer base (PVA) and hydrophobic nature of some 
progestin (such as DES), sedimentation studies should be carried out to ensure adequate dispersion 
of progestins in the polymeric solution throughout the film product manufacturing process. In 
addition, DES is susceptible to oxidation. Antioxidants, such as Vitamin E, should be considered 
in the formulation for stabilizing the DES. Moreover, Cremophor may oxidize DES leading to a 
decrease in released drug amount. Other surfactants without any potential to impact the API should 
be used in dissolution testing of products containing DES. 
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6.0  NOVELTY AND SIGNIFICANCE 
This study investigated the SC platform for incorporating progestins into polymeric films. The 
polymeric films we generated had similar and stable physical characteristics. The successful 
incorporation of a panel of progestins with various physiochemical properties demonstrated the 
versatility of this platform. Moreover, these progestins are currently used as contraceptive agents. 
On one hand, the clinical progestin films can serve as a practical solution for the urgent need of 
more novel birth control options. On the other hand, the data with progestin films developed in 
this project illustrated that this SC platform is capable of application of dual prevention 
(contraception and HIV prevention) therapies.   
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7.0  FUTURE PLANS 
The vagina can be used to achieve both local and systemic drug exposure. The use of vaginal 
administration for systemic drug delivery has been well established. The vagina also contains a 
vast network of blood vessels making systemic delivery of drugs possible (83). This route offers 
certain advantages, such as avoidance of gut and hepatic first-pass metabolism (73). A study (84) 
of the pharmacokinetics of vaginal maraviroc gels in rhesus macaques indicated that the peak 
plasma concentration was achieved 2 hours after gel application. Another study (85) investigated 
the pharmacokinetics of quick-dissolving vaginal films incorporating a poorly soluble 
antiretroviral drug, IQP-0528. In this study, drug concentration monitored in the vaginal fluid 
illustrated that the films could deliver similar levels of drug as gels, for up to 24 hours after 
application. These studies demonstrate feasibility for delivery of progestins within the vagina and 
rapid uptake into the systemic circulation.  
The primary mechanism of contraception for progestin is to inhibit ovulation, which 
depends on the negative feedback of high levels of progestin on hypothalamus and pituitary. 
Therefore, to achieve contraceptive effects, it is desirable that progestin obtain stable high serum 
levels continuously. The fast-release progestin films we manufactured in this project deliver a daily 
dose of progestins. For daily-use dosage forms, such as pills and vaginal films in this project, 
timing and duration of administration are critical (17). For example, the biological half-life of ENG 
is about 25 hours. The steady-state levels of ENG are achieved after about 8 to 10 days of daily 
administration (86). In order to achieve optimal contraceptive effects, these progestin films should 
be used daily at the same time of the day.  
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A study (38) showed that long-acting reversible contraception (LARC) lead to better 
patient compliance than daily used contraceptive methods. To this end, the progestin polymeric 
vaginal films can be further developed as extended-release (ER) progestin films for contraception. 
Ideally, an extended-release (ER) vaginal film can stay in the vagina to achieve controlled 
progestin release. Similar to contraceptive implants, IUDs, an ER vaginal film would not require 
frequent administration, resulting in better patient’s compliance (38).  
The data generated in this project can also be applied for multi-purpose prevention therapy 
(MPT). The goal of MPT is to achieve multiple prevention effects at the same time. By combining 
APIs with different pharmacological effects, one dosage form can achieve MPT. The solvent-cast 
film platform used in this project was initially evaluated in the clinic for vaginal delivery of 
dapivirine (DPV), a non-nucleoside reverse transcriptase inhibitor (1) for HIV prevention. This 
film platform has already been studied in in vitro evaluations for its capacity to deliver multiple 
APIs in one film (51). Over sixty-two percent of women of reproductive age currently use 
contraception, 10.6 million women of which are using hormonal contraceptive methods. Therefore, 
combining a hormonal contraceptive film with an anti-retroviral agent could be developed to 
prevent both unintended pregnancy and HIV infection. 
In addition, there are certain considerations should be addressed in future film development. 
The normal vaginal pH level is between 3.8 and 4.5. The slightly acidic environment is critical to 
avoid infections and diseases (87). Thus, vaginal films should maintain an optimal pH for vaginal 
health. To further ensure the safety of vaginal films, standard microbicide safety tests should be 
performed to assess Lactobacillus compatibility (1); in vitro and in vivo toxicity studies should 
also be considered as criteria in the evaluation of the vaginal film. 
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Moreover, early work by Johnson and Masters (88) showed that the drug distribution and 
coverage of vagina tissue vary considerably with the nature of the delivery system. Therefore, in 
addition to those common criteria mentioned above, other critical film properties are required to 
achieve intended effects. For example, the drug should penetrate the epithelium in order to achieve 
systemic effects. Therefore, permeability profiles should be tested; the drug should distribute 
uniformly throughout the vaginal cavity if local effect is intended. Thus, study of the products 
ability to uniformity distribute drug throughout the vagina is critical for films with intended topical 
drug delivery. For controlled/extended films, bio-adhesion is a preferable film characterization. 
However, at the same time, it may serve as a permeability barrier for drugs (73). Therefore, film 
swelling (swelling index), bio-adhesion (bio-adhesive strength), and retention (drug amount 
retained on vaginal mucosa) studies should be performed as critical film characterizations (89).  
 56 
APPENDIX A 
2D CHEMICAL STRUCTURE OF PROGESTINS(70) 
Desogestrel (DES) Etonogestrel (ENG) 
  
Dienogest (DNG) Ulipristal Acetate (UPA) 
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